Free Trial
→ Wall Street Legend Issues Urgent AI Stock Warning (From Chaikin Analytics) (Ad)tc pixel

Helix BioPharma (TSE:HBP) Reaches New 12-Month High - Time to Buy?

Written by MarketBeat
September 10, 2025
Helix BioPharma logo with Medical background

Key Points

  • Helix BioPharma Corp. reached a new 52-week high of C$1.48, trading at this price with a volume of 136 shares after closing at C$1.45.
  • The company specializes in cancer drug development and is focused on immuno-oncology therapies, including pipeline candidates L-DOS47 and V-DOS47.
  • Helix BioPharma has a market cap of C$110.75 million and a PE ratio of -1.41, indicating it is currently operating at a loss.
  • Five stocks to consider instead of Helix BioPharma.

Helix BioPharma Corp. (TSE:HBP - Get Free Report)'s stock price hit a new 52-week high on Monday . The stock traded as high as C$1.48 and last traded at C$1.48, with a volume of 136 shares. The stock had previously closed at C$1.45.

Helix BioPharma Price Performance

The company's fifty day moving average price is C$1.13 and its two-hundred day moving average price is C$0.97. The firm has a market cap of C$110.75 million, a PE ratio of -1.41 and a beta of -0.45.

About Helix BioPharma

(Get Free Report)

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Helix BioPharma Right Now?

Before you consider Helix BioPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Helix BioPharma wasn't on the list.

While Helix BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.